SEC Form 4 · accession 0001651844-17-000004

NYMOX PHARMACEUTICAL CORP · NYMX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jun 19, 2017

Accepted (ET)

Jun 21, 2017 · 4:49 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001018735

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jun 19, 2017	P	600	$3.77	A	3,008,150	D
Common Stock	Jun 19, 2017	P	500	$3.78	A	3,008,650	D
Common Stock	Jun 19, 2017	P	2,000	$3.79	A	3,010,650	D
Common Stock	Jun 19, 2017	P	1,900	$3.80	A	3,012,550	D
Common Stock	Jun 20, 2017	P	2,000	$3.75	A	3,014,550	D
Common Stock	Jun 20, 2017	P	300	$3.76	A	3,014,850	D
Common Stock	Jun 20, 2017	P	2,200	$3.77	A	3,017,050	D
Common Stock	Jun 20, 2017	P	500	$3.79	A	3,017,550	D
Common Stock	Jun 21, 2017	P	500	$3.75	A	3,018,050	D
Common Stock	Jun 21, 2017	P	3,500	$3.76	A	3,021,550	D
Common Stock	Jun 21, 2017	P	1,000	$3.77	A	3,022,550	D
Common Stock	holding	—	—		—	49,550	I	Trust
Common Stock	holding	—	—		—	49,550	I	trust
Common Stock	holding	—	—		—	49,550	I	Trust
Common Stock	holding	—	—		—	49,550	I	Trust
Common Stock	holding	—	—		—	49,550	I	Trust
Common Stock	holding	—	—		—	49,550	I	Trust
Common Stock	holding	—	—		—	49,550	I	Trust
Common Stock	holding	—	—		—	49,550	I	Trust
Common Stock	holding	—	—		—	49,550	I	Trust
Common Stock	holding	—	—		—	49,550	I	Trust
Common Stock	holding	—	—		—	49,550	I	Trust

No Table II lines on this filing.